Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Increases By 3,947.9%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 388,600 shares, a growth of 3,947.9% from the September 30th total of 9,600 shares. Based on an average trading volume of 1,390,000 shares, the short-interest ratio is currently 0.3 days. Currently, 10.5% of the shares of the stock are sold short.

Institutional Trading of Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 5.74% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on BPTH shares. StockNews.com began coverage on Bio-Path in a research note on Wednesday. They issued a “sell” rating for the company. Roth Mkm restated a “buy” rating and set a $20.00 price target on shares of Bio-Path in a research report on Monday, July 8th.

Bio-Path Stock Up 0.9 %

Shares of NASDAQ BPTH traded up $0.01 during midday trading on Friday, reaching $1.08. 61,303 shares of the stock were exchanged, compared to its average volume of 1,213,142. The company has a 50 day simple moving average of $1.05 and a 200 day simple moving average of $1.84. Bio-Path has a twelve month low of $0.85 and a twelve month high of $14.42.

Bio-Path (NASDAQ:BPTH) last posted its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the previous year, the company posted ($10.60) earnings per share. On average, equities research analysts predict that Bio-Path will post -6.2 earnings per share for the current year.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.